Our Mission

image

Vince and David living with transthyretin (ATTR) amyloidosis

image

Bill, living with transthyretin (ATTR) amyloidosis and his wife Maura

Transforming
lives
of people with severe diseases by developing potentially curative genome editing treatments

image

Pam, who lost her husband to acute myeloid leukemia (AML).

Many of us in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Genetic, oncological or immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.

Intellia’s researchers work tirelessly to harness CRISPR/Cas9 genome editing technology for human therapeutic use. In fact, one of Intellia’s co-founders, Jennifer Doudna, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. At Intellia, we are humbled to have a hand in making what we believe to be medical history. As a leader in this space, our responsibility and commitment to patients is critical in our pursuit of developing novel, potentially curative therapeutics utilizing CRISPR/Cas9 technology.

More specifically, we are employing a modular genome editing platform to create diverse in vivo and ex vivo therapeutics, spanning a range of disease indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Core Values

Our values are at the heart of our company’s identity and culture.

Core Values

One

One is respect for individuals; our unique qualities and strengths; our own ways to understand, learn and improve. One is our single-minded determination to excel; to succeed together. One is you and us – trusting and counting on every single one of us.

Explore

Explore because we seek new ways to tackle disease. Explore with unbounded minds… free from assumptions, open to ideas. Explore by staying curious and pushing boundaries. Explore means thinking of new ways to overcome obstacles.

Disrupt

Disrupt by thinking courageously… and creating a better future. Disrupt by defying conformity; interrogating the status quo; questioning our momentum. Disrupt with challenging thoughts, and using skepticism and imagination to develop new ways, innovative solutions.

Deliver

Deliver by focusing on the objective and your determination to complete the task. Deliver by advancing relentlessly and by maintaining high standards… even when nobody is watching. Deliver by staying accountable and pulling your weight. Deliver because patients are counting on us to make the promise a reality. Get it done.

Management Team

Our leaders bring all the necessary skills and experience from world-leading organizations, and embody Intellia’s values – one, explore, disrupt, deliver – to deliver genome editing therapeutics. Our team comprises experts in all aspects of developing human therapeutics, including preclinical research, manufacturing and clinical development.

John Leonard, M.D.

John Leonard, M.D.

President and Chief Executive Officer
James Basta, J.D.

James Basta, J.D.

Executive Vice President, General Counsel and Corporate Secretary
Eliana Clark, Ph.D.

Eliana Clark, Ph.D.

Senior Vice President, Technical Operations
Christine Foster, D. Phil.

Christine Foster, D. Phil.

Senior Vice President, Business Development and Alliance Management
Glenn Goddard

Glenn Goddard

Executive Vice President, Chief Financial Officer
Derek Hicks

Derek Hicks

Executive Vice President, Chief Business Officer
Ian Karp

Ian Karp

Senior Vice President, Investor Relations and Corporate Communications
David Lebwohl, M.D.

David Lebwohl, M.D.

Executive Vice President, Chief Medical Officer
Birgit Schultes, Ph.D.

Birgit Schultes, Ph.D.

Senior Vice President, Head of Cell Therapies
Laura Sepp-Lorenzino, Ph.D.

Laura Sepp-Lorenzino, Ph.D.

Executive Vice President, Chief Scientific Officer
Marika St. Amand

Marika St. Amand

Senior Vice President, Chief Human Resources Officer

Board of Directors

Industry veterans and experienced investors with demonstrated skills in building leading biotechnology companies.

Frank Verwiel, M.D.

Frank Verwiel, M.D.

Chairman of the Board
Fred Cohen, M.D., D.Phil, F.A.C.P.

Fred Cohen, M.D., D.Phil, F.A.C.P.

Independent Director
John F. Crowley

John F. Crowley

Independent Director
Caroline Dorsa

Caroline Dorsa

Independent Director
Jean-François Formela, M.D.

Jean-François Formela, M.D.

Independent Director
Jesse Goodman, M.D.

Jesse Goodman, M.D.

Independent Director
Georgia Keresty, Ph.D., M.P.H.

Georgia Keresty, Ph.D., M.P.H.

Independent Director
John Leonard, M.D.

John Leonard, M.D.

President and CEO, Intellia

Our Partners

logo
  • Intellia entered into a license and collaboration agreement with Regeneron, where both companies are researching, developing and commercializing CRISPR/Cas-based therapeutic products primarily focused on genome editing in the liver. Intellia and Regeneron expanded their collaboration in 2020, with Regeneron having an additional option to extend by two more years in the future, View Press Release
  • Intellia’s first in vivo product candidate, NTLA-2001, seeks to treat all forms of transthyretin (ATTR) amyloidosis, regardless of disease type, with a single dose of treatment. NTLA-2001 is part of a co-development/co-promotion agreement between Intellia, the lead development and commercialization party, and Regeneron.
  • Intellia and Regeneron are co-developing potential hemophilia A and B CRISPR/Cas9-based treatments using their jointly owned targeted transgene insertion capabilities. Regeneron is leading development for both hemophilia A and hemophilia B development programs.
  • Regeneron also has a royalty-bearing, non-exclusive license to certain Intellia intellectual property (IP) to independently develop and commercialize up to 10 ex vivo CRISPR/Cas9 products limited to defined cell types. Intellia’s license to Regeneron does not include access to IP directed to NTLA-5001, Intellia’s wholly owned development candidate for the treatment of acute myeloid leukemia, or other IP directed to Intellia’s ex vivo targets, programs or proprietary cell engineering processes.
logo
  • Intellia entered into a strategic collaboration and license agreement with Novartis, focusing on accelerating the development of new ex vivo CRISPR/Cas9-based therapies using chimeric antigen receptor T cells and hematopoietic stem cells (HSCs). The collaboration portion of the agreement ended in December 2019, with each party continuing to advance selected programs after the collaboration term.
  • Novartis is currently pursuing a sickle cell disease treatment based on genome editing of HSCs, using CRISPR/Cas9 RNA guides identified through Intellia’s cell therapy research collaboration with Novartis. Intellia is eligible to receive additional downstream success-based milestones and royalties. View Press Release
logo
  • Intellia is working with Ospedale San Raffaele (OSR) to engineer optimized T cell-based cancer therapies. View Press Release
  • The collaboration has resulted in Intellia’s first ex vivo development candidate, which is a T cell therapy for acute myeloid leukemia targeting the Wilms’ Tumor protein (WT1). Intellia has also exercised its option to obtain an exclusive license to OSR’s intellectual property developed under the collaboration, including patent applications directed to WT1-specific T cell receptors.
logo
  • Intellia and Teneobio, Inc. entered into a research collaboration and licensing agreement to use Teneobio’s Heavy Chain Antibodies (UniAbs®) for Intellia’s next-generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs® against targets that can be used in engineered cell therapies for various life-threatening diseases. Intellia will have the option to exclusively license the novel antibodies for global development and commercialization. View Press Release
logo
  • Intellia launched a new universal CAR-T cell therapy company in collaboration with Blackstone Life Sciences and Cellex Cell Professionals GmbH (“Cellex”). The new company will combine clinical-stage universal CAR-T platforms with Intellia’s differentiated allogeneic cell engineering platform to develop therapies for immuno-oncology and autoimmune diseases. View Press Release
logo
  • In October 2021, Intellia and SparingVision announced a collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for up to three ocular targets addressing diseases with significant unmet medical need. View Press Release
  • As part of this collaboration, SparingVision will lead and fund the preclinical and clinical development for the genome editing product candidates pursued under the collaboration. In addition, the parties will research and develop novel self-inactivating AAV vectors and LNP-based approaches to address delivery of CRISPR/Cas9 genome editing reagents to the retina.
  • Intellia will receive an equity stake in SparingVision and will have an option to obtain exclusive U.S. commercialization rights for two of three ocular targets.
logo
  • In January 2022, Intellia and Kyverna announced a licensing and collaboration agreement for the development of an allogeneic CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases. View Press Release
  • As part of the agreement, Intellia granted Kyverna rights to use its proprietary ex vivo CRISPR/Cas9-based allogeneic platform for the development of KYV-201, a next-generation CD19 CAR T-cell investigational candidate for the treatment of select autoimmune diseases. In exchange, Intellia received an equity stake in Kyverna and made an additional investment in Kyverna. Kyverna will lead and fund preclinical and clinical development for KYV-201.
  • Intellia may also exercise an option to lead U.S. commercialization for KYV-201 under a co-development and co-commercialization agreement.

Partnering

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is focused on rapidly moving transformative therapies towards the clinic. We are proud to count biopharmaceutical companies and leading academic institutions as partners – organizations that share our determination to revolutionize medical science.

We seek strategic collaborators to help unlock the full potential of CRISPR/Cas9 genome editing. We scout for cutting-edge technologies that advance the application of CRISPR/Cas9 for human therapeutics and our genome editing platforms, including:

  • Genome modifying technologies
  • Recombination and DNA repair technologies
  • RNA therapeutic technologies
  • Therapeutic delivery of nucleic acids or ribonucleoproteins – viral and chemical
  • Engineered immune cell technologies
  • Novel target identification

If you are interested in exploring CRISPR/Cas9 genome editing science and its translation into human therapies, or if your technology could advance the science, please contact us at bd@intelliatx.com.